AGPU · Predictive Oncology Inc.

Axe Compute Inc. reported its fiscal year 2025 results, marking a foundational transition from Predictive Oncology Inc. to an AI compute infrastructure company. The financial results were heavily impacted by non-cash charges associated with this strategic pivot. The Company recognized a net loss of $232.9 million, a significant increase from the $12.7 million loss in the prior year. This deterioration was driven primarily by $152.5 million in unrealized losses on digital assets (specifically the ATH token) and a $52.7 million loss on derivative instruments, reflecting the volatility inherent in its new digital asset treasury strategy. Operational revenue remained nominal at $0.13 million, derived solely from the legacy Helomics Drug Discovery Services business, which is currently under strategic review for potential sale or partnership. The Company successfully completed a $343.5 million capital raise through PIPE transactions in October 2025, which transformed the balance sheet from a stockholders' deficit of $0.2 million to equity of $47.7 million. Cash and cash equivalents increased to $10.8 million as of December 31, 2025. Management indicated that priorities for 2026 include generating initial compute revenue, pursuing ATH staking yields, and completing the strategic alternatives process for the legacy business.